Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Prospective, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of EV06 Ophthalmic Solution, in Improving Distance Corrected Near Vision in Subjects With Presbyopia

Next Previous
Trial Profile

A Phase 1/2 Prospective, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of EV06 Ophthalmic Solution, in Improving Distance Corrected Near Vision in Subjects With Presbyopia

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lipoic acid choline ester (Primary)
  • Indications Presbyopia
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Encore Vision

Most Recent Events

  • 05 May 2016 Results from this trial were presented at the Ophthalmic Innovation Summit, according to an Encore Vision media release.
  • 05 May 2016 Results published in an Encore Vision media release.
  • 02 May 2016 According to an an Encore Vision media release, additional results will be presented during the Ophthalmology Innovation Showcase at the 2016 Ophthalmology Innovation Summit at the American Society of Cataract and Refractive Surgeons Symposium (OIS@ASCRS).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top